Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Alendronic acid
Drug ID BADD_D00066
Description Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label][A959].
Indications and Usage Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of bone[FDA Label][A959,A176750]. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance <35mL/min[FDA Label].
Marketing Status approved
ATC Code M05BA04
DrugBank ID DB00630
KEGG ID D07119
MeSH ID D019386
PubChem ID 2088
TTD Drug ID D09KLR
NDC Product Code Not Available
UNII X1J18R4W8P
Synonyms Alendronate | 4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate | Aminohydroxybutane Bisphosphonate | MK-217 | MK 217 | MK217 | Alendronate Monosodium Salt, Trihydrate | Alendronate Sodium | Fosamax
Chemical Information
Molecular Formula C4H13NO7P2
CAS Registry Number 66376-36-1
SMILES C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Intracranial mass17.11.01.0170.000044%Not Available
Spinal flattening15.10.04.0110.000066%Not Available
Allergy to animal10.01.03.0510.000044%Not Available
Allergy to arthropod bite10.01.03.0350.000044%Not Available
Anisocoria17.02.11.009; 06.05.03.0130.000044%Not Available
Arthrofibrosis15.01.08.0160.000044%Not Available
Benign gastric neoplasm16.05.03.005; 07.20.01.0170.000044%Not Available
Blood loss anaemia01.03.02.018; 24.07.01.0880.002091%Not Available
Bone hypertrophy15.02.04.0410.000141%Not Available
Breast dysplasia21.05.04.0100.000044%Not Available
Chest wall cyst16.18.01.012; 15.09.01.0120.000044%Not Available
Colorectal adenoma16.05.02.009; 07.20.01.0190.000374%Not Available
Degenerative bone disease15.02.04.0440.000044%Not Available
Dermal sinus23.07.05.0090.000198%Not Available
Device intolerance08.07.01.0150.000088%Not Available
Dilated cardiomyopathy02.04.01.0170.000088%Not Available
Enchondromatosis16.11.01.002; 15.09.01.0130.000044%Not Available
Femoroacetabular impingement15.01.08.017; 12.04.03.0110.000044%Not Available
Focal dyscognitive seizures17.12.02.0050.000044%Not Available
Foreign body reaction23.03.15.012; 08.01.05.0160.000044%Not Available
Gait inability17.02.05.069; 08.01.02.0110.000176%Not Available
Gastrointestinal mucosal exfoliation07.11.01.0370.000066%Not Available
Giant cell arteritis06.07.02.010; 24.12.02.003; 17.08.02.033; 10.02.02.0320.000132%Not Available
Graves' disease10.04.08.014; 06.09.04.009; 05.02.02.0090.000066%Not Available
Haemangioma of bone24.03.06.013; 16.11.02.004; 15.09.01.0140.000066%Not Available
Hyperaesthesia teeth07.09.06.0050.000440%Not Available
Idiopathic urticaria23.04.02.015; 10.01.06.0150.000044%Not Available
Immune thrombocytopenia10.02.01.083; 01.08.01.0130.000066%Not Available
Intervertebral disc calcification15.10.01.0080.000044%Not Available
Intestinal mucosal tear12.01.17.010; 07.11.01.0410.000044%Not Available
The 37th Page    First    Pre   37 38 39    Next   Last    Total 39 Pages